Pharmacist prescribing in critical care: an evaluation of the introduction of pharmacist prescribing in a single large UK teaching hospital

Verity J Cross,1 James T Parker,2 Marie-Christine Y L Law Min,2 Richard S Bourne2

ABSTRACT

Objectives To evaluate the introduction of pharmacist independent prescribing activity across three general critical care units within a single large UK teaching hospital. To identify the prescribing demographics including total of all prescriptions, number prescribed by pharmacists, reason for pharmacist prescription, range of medications prescribed, pharmacist prescribing error rate and the extent of pharmacist second ‘clinical check’.

Methods Retrospective evaluation of e-prescribing across all general critical care units of a single large UK teaching hospital. All prescribing data were downloaded over a 1-month period (May to June 2016) with analysis of pharmacist prescribing activity including rate, indication, therapeutic class and error rate.

Results In total, 5374 medicines were prescribed in 193 patients during the evaluated period. Prescribing pharmacists were available on the units on 60.4% (342/576) of days, during their working hours and accounted for 576/5374 (10.7%) of medicines prescribed in 65.2% (126/193) of patients. The majority (342/576) of pharmacist prescriptions were for new medicines. Infections, central nervous system, and nutrition/blood were the top three British National Formulary (BNF) therapeutic categories, accounting for 63.4% (349/576) of all pharmacist prescriptions. The critical care pharmacist prescribing error rate was 0.18% (1/550).

Conclusions Pharmacist independent prescribers demonstrated a high degree and wide-ranging scope of prescribing activity in general critical care patients. Pharmacists contributed a significant proportion of total prescribing, despite less than full service coverage. Prescribing activity was also safe with a very low error rate recorded.

INTRODUCTION

Clinical pharmacists make an essential contribution to the safe and effective use of medicines in critically ill patients.1 Direct patient care via pharmacist medication review is an important resource for reducing medication errors and optimising medication use.2 Recommendations for changes to medication therapy related to these medication reviews have very high acceptance rates by critical care medical teams.3,4 Pharmacist prescribing to action the outcomes of their own medication reviews would be anticipated to reduce the workload of medical colleagues and improve efficiency. Moreover, pharmacist instigation of medication therapy planned by the multidisciplinary team may also offer advantages with respect to getting treatment right the first time in specific areas, for example, therapeutic drug monitoring or drug dosing in multiorgan failure.

Pharmacists have been able to practise as independent prescribers in the UK since 2006.7 Baqir et al reported the scope and safety of pharmacist prescribing practice in general ward patients in a UK setting.8 In critical care, a 2014 survey of UK critical care pharmacists identified that by 2017, most pharmacists would be practising as prescribers.4 The survey also provided some indication of the perceived benefit, scope and place for pharmacist prescribing in this specialty.4 However, to date, there are limited data on actual prescribing practice by critical care pharmacists.9

The aim of the present study was to describe the current scope and safety of prescribing activity undertaken by critical care pharmacists after the recent introduction of this service in a single large UK teaching hospital.

METHODS

The evaluation of prescribing activity was conducted over a 1-month period (19 May−19 June 2016; 32 days) across three critical care units (CCUs) within a single large UK teaching hospital. The study period was dictated by the timing of local project approval. All participating units were general CCUs (one
intensive care unit (ICU), one high dependency unit (HDU) and one mixed ICU/HDU comprising a total of 42 beds. All general CCUs used electronic prescribing (MetaVision; iMDsoft, Massachusetts, USA). The e-prescribing database had been customised and checked by pharmacists and included default doses for most medicines. Specialist neuro and cardiac CCUs were excluded as electronic prescribing was unavailable. A team of critical care pharmacists provided the clinical pharmacy service across all the general and specialist critical care units of the trust. The pharmacists were working at foundation, advanced or mastery level in critical care pharmacy practice. At the time of evaluation, 5 of the 10 pharmacists were practising prescribers. In the general CCUs, routine care was provided by three pharmacists per weekday and one pharmacist at weekends; the prescribing status of each pharmacist did not influence their inclusion in the rota.

All prescribing data were downloaded directly from the e-prescribing system into an Excel database (Microsoft Office, Washington, USA) for manipulation, for example, identification of pharmacist prescriptions. Electronic medical notes were then individually reviewed by VC (principal author and non-prescribing clinician) at foundation level in critical care pharmacy practice for further details on the indication of pharmacist prescribing and data related to second pharmacist ‘clinical check’ activity. The indications for pharmacist prescribing were recorded and categorised according to a 2014 survey of critical care pharmacist practice and a 2014 study of pharmacist prescribing in general hospital practice. The medicine prescriptions were categorised according to the primary indication for prescribing with determination from the medical note entry.

For the purposes of investigating error rate, an error was defined as ‘any prescription which was incorrect at the time of prescribing and therefore needed subsequent amendment’. All critical care pharmacists were requested to inform the lead investigator (VC) of any pharmacist prescribing errors identified and details. VC also retrospectively reviewed all pharmacist prescriptions and medical notes to identify any errors.

Nutritional supplements (eg, carbohydrate drinks) and maintenance fluids without additives were excluded from analysis.

Descriptive statistics were used to report prescribing data. The study was designated and registered as a service evaluation with the clinical effectiveness unit at the trust (CEU no 7372).

RESULTS

Over the 1-month evaluation period, a total of 5374 individual medicine prescriptions in 193 patients were completed by all prescribers within critical care. Pharmacists contributed 576 of these medicine prescriptions, of which critical care pharmacist independent prescribers (PIPs) prescribed 550 medicines and a specialist nutrition PIP prescribed a further 26 medicines. Pharmacists therefore provided 10.7% of the prescribing workload (576/5374).

Most critical care patients (126/193 (65.3%)) had at least one medicine prescribed for them by a pharmacist.

A second ‘clinical check’ was undertaken by another critical care pharmacist retrospectively in approximately half of all medicine prescriptions (286/550 (52%)). The timescale of this second ‘clinical check’ was not recorded, and the second clinical checks were noted as having been performed if another pharmacist approved the prescription at any time within the patient’s critical care stay. These second ‘clinical checks’ identified no errors. During full review of all pharmacist prescriptions by the investigator pharmacist (VC), one error was identified, providing an error rate of 0.18% (1/550) during the period evaluated. The single error identified was classified as ‘wrong dose’. The patient received an unadjusted paracetamol dose despite acute weight loss to <50 kg; this error was rectified by another pharmacist the following day.

The PIPs prescribed medicines from a wide range of therapeutic classes (Table 1). The only two chapters of the British National Formulary (BNF) not prescribed from were chapters 14 (malignant disease and immunosuppression) and 10 (musculoskeletal and joint disease).

The rationale for pharmacist prescribing was investigated (Figure 1), and the categories used to classify the data were derived from a questionnaire distributed to critical care pharmacist prescribers in 2014. Some of the categories were amended when the results began to show recurring themes, for example, antibiotics was split into ‘new antibiotics’ and ‘antibiotic dose changes’.

Table 1

<table>
<thead>
<tr>
<th>Chapter of the BNF (10)</th>
<th>Percentage of medicines (N=576)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections</td>
<td>23.0 (132)</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>18.9 (109)</td>
</tr>
<tr>
<td>Nutrition and blood</td>
<td>18.7 (108)</td>
</tr>
<tr>
<td>Cardiovascular system</td>
<td>14.7 (85)</td>
</tr>
<tr>
<td>Gastrointestinal system</td>
<td>8.2 (47)</td>
</tr>
<tr>
<td>Endocrine system</td>
<td>6.4 (37)</td>
</tr>
<tr>
<td>Respiratory system</td>
<td>2.6 (15)</td>
</tr>
<tr>
<td>Anaesthesia</td>
<td>2.6 (15)</td>
</tr>
<tr>
<td>Eye</td>
<td>2.1 (12)</td>
</tr>
<tr>
<td>Ear, nose and oropharynx</td>
<td>1.6 (9)</td>
</tr>
<tr>
<td>Skin</td>
<td>0.5 (3)</td>
</tr>
<tr>
<td>Obstetrics, gynaecology and urinary tract disorders</td>
<td>0.3 (2)</td>
</tr>
<tr>
<td>Immunological products and vaccines</td>
<td>0.2 (1)</td>
</tr>
<tr>
<td>Other</td>
<td>0.2 (1)</td>
</tr>
<tr>
<td>Malignant disease and immunosuppression</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Musculoskeletal and joint diseases</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

DISCUSSION

To our knowledge, this is the first study that has specifically evaluated the practice of prescribing pharmacists in UK CCUs. Critical care PIPs contributed a significant proportion of total prescriptions, with a wide scope of practice, prescribing mostly new medicines with a very low error rate. This single centre evaluation benefits from a data analysis of pharmacist prescribing with more than 30 days of continuous data, 7 days per week across three general CCUs.

Approximately 11% (576/5374) of all prescriptions during the evaluation period were prescribed by pharmacists, despite PIPs covering only approximately 60% (58/96) of clinical pharmacy shifts across the CCUs during the study period, reflecting...
the incomplete introduction of this relatively new service. Pro
rata this suggests that this figure could rise between 15% and
20% with a ‘full’ PIP service—where PIPs cover 100% of all
clinical pharmacy shifts across the CCUs. This proportion is
significantly higher than the results of a national 2014 survey of
critical care pharmacist prescribing, where 90% of pharmacists
estimated that their practice accounted for 10% or less of all new
prescriptions.

Only 52% (286/550) of PIP prescriptions received a second
‘clinical check’ by another pharmacist during the study.
Throughout the evaluation, a single pharmacist was assigned to
each CCU—often for up to 5 days to allow for service conti-
nuity. The availability of a second pharmacist on the unit to
provide ‘clinical checking’ was therefore not routine. This,
combined with high patient turnover and the fact that delayed
‘self-checking’ was not included, may account for the relatively
low rate of ‘clinical checking’ seen for PIP prescriptions. As
such, pharmacist prescribers may be less likely to benefit from
the safety support clinical pharmacists routinely provide to other
prescribers.

The low error rate of pharmacist prescribing is comparable
to other reports of pharmacist prescribing error rate ranging
from 0% to 1.2%. The error in this study was identified
retrospectively by the investigating pharmacist and not self-re-
ported by the PIP. The error rate in the study may have been
positively influenced by the e-prescribing system having default
dosing for many drugs, and the fact that the principal investi-
gator (VC) reviewing the prescriptions was a relatively junior
critical care pharmacist. No PIP errors were identified by other
pharmacists throughout the study, although pharmacists were
instructed to report any errors seen throughout the data collec-
tion period.

This error rate compares favourably with medical staff
prescribing, with large studies suggesting error rates between
7% and 9%. The percentage of pharmacist prescriptions needed to correct
a prescribing error was lower than the comparable study on
general wards (5.2% vs 7.5%). This may reflect the extent of the
medication safety resources employed within critical care
e-prescribing, specialist critical care pharmacist 7 days/week,
extensive critical care guidelines, education sessions, robust
and responsive clinical incident reporting system) and use of
advanced nurse practitioners.

### Table 2
Comparison of critical care and general ward report by reason for medicine prescribing

<table>
<thead>
<tr>
<th>Reason for Prescribing</th>
<th>Critical Care</th>
<th>General Ward (8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New medicine</td>
<td>59.4% (342)</td>
<td>18.7%</td>
</tr>
<tr>
<td>Medicine dose change</td>
<td>18.6% (107)</td>
<td>1.5%</td>
</tr>
<tr>
<td>Regular medication not prescribed</td>
<td>16.8% (97)</td>
<td>68.1%</td>
</tr>
<tr>
<td>Incorrectly prescribed medicines</td>
<td>5.2% (30)</td>
<td>7.5%</td>
</tr>
</tbody>
</table>

**Critical care pharmacist independent prescribers (PIPs) covered these units on 60.4% (58/96) of days during normal working hours (08:00 to 16:30). These data suggest that each PIP prescribed an average of 10 medicines/day, although this varied greatly according to individual practitioner and availability of multiple pharmacists (0–44 medicines/day).**

Figure 1  Graph demonstrating the indications for pharmacist prescribing expressed as a percentage of total pharmacist prescriptions. AKI, acute kidney injury; CNS, central nervous system; CVVH, continuous venovenous haemofiltration; EI, extended infusion; SUP, stress ulcer prophylaxis; VTE, venous thromboembolism.
Medicines prescribed

The General Pharmaceutical Council registrant survey in 2013\(^\text{18}\) reported that pharmacists most commonly prescribe antibiotics, analgesia, anticoagulation and cardiovascular medications. Antibiotics and cardiovascular medications have proven to be a recurring theme,\(^\text{19,20}\) as well as gastrointestinal, respiratory and eye preparations. A multicentre study in Northumbria\(^\text{2}\) revealed that items were prescribed by PIPs from all areas of the BNF except chapters 8, 14 and 15 (Malignant disease and immunosuppression, Immunological products and vaccines and Anaesthesia). In this critical care study, pharmacists prescribed from a wide range of therapeutic classes, most notably in the areas of infections, central nervous system, blood/nutrition and cardiovascular system disorders. There were no prescriptions for BNF chapters 8 and 10—infection/immunosuppression and musculoskeletal disorders. This may reflect critical care pharmacists working within their competencies or perhaps simply patient demographics over the evaluation period.

The reasons why pharmacists are prescribing were classified by two methods to facilitate useful comparison with existing reports of pharmacist prescribing in acute hospital patients.\(^\text{4,8}\)

A survey of UK critical care pharmacist prescribing activity undertaken in 2014\(^\text{4}\) reported that the primary indications respondents prescribed for were: dose adjustment, change of medication route or formulation and correction of prescribing error (in decreasing order).\(^\text{8}\) Using comparable categories, the results of this evaluation indicated that the top three reasons for prescribing within the CCUs were ‘regular medication not prescribed’, ‘new antibiotic’ and ‘new medicine for condition not listed in trust guidelines’.

Though there initially seems to be very little overlap between the questionnaire results and the data captured on the CCUs, this is in part owing to having two categories involving dose amendment (‘antibiotic dose amendment’ and ‘dose adjustment not including antibiotics’), adding these categories together makes ‘dose adjustment’ a top three indication.

The high frequency of antibiotic prescriptions resulted in two antibiotic categories (‘new antibiotic’ and ‘antibiotic dose amendment’) to provide further information on pharmacist prescribing in practice. On all units, pharmacists attended the multiprofessional ward rounds including microbiology reviews. During these reviews, changes in choice of antimicrobial therapy are made in line with antimicrobial stewardship principles. Attending these daily ward rounds gives the pharmacists the most current information about the most appropriate antibiotics to use in specific patients, and they are then able to amend or change the antimicrobial prescription, utilising pharmacokinetic and pharmacodynamic principles, for example, employing effective loading doses as well as extended infusions of beta-lactam agents in order to optimise therapeutic plasma levels and facilitate their time-dependent bactericidal activity.\(^\text{21}\)

Indeed, antimicrobials accounted for approximately 25% (132/576) of all prescriptions, suggesting an important area of pharmacist prescribing practice and a clear role for all professionals in the treatment of infections: medical/nursing staff identify infection/sepsis; microbiologists guide therapy and clinical pharmacists optimise therapy.

Baqir et al reported a multicentre study of pharmacist prescribing in acute hospital inpatients receiving general ward care.\(^\text{8}\) A notable difference between the results of this critical care study and that undertaken in ward-based patients\(^\text{8}\) is that critically ill patients receive a higher rate of new medicines from pharmacists (59.4% vs 18.7%) rather than continuity of regular medicines not prescribed (16.8% vs 68.1%). The acuity of critical care patient therapeutics means more frequent assessments, and changes in therapy are required and these include medication reviews and prescribing outcomes. This may partly explain why pharmacists working in critical care prescribed medicines for approximately two-thirds of patients rather than the less than forty per cent reported by Baqir et al.\(^\text{8}\) In this study of critical care patients, dose adjustment explained approximately one-fifth (107/576) of pharmacist prescriptions but only a tiny minority (1.5%) of those reported in ward-based patients.\(^\text{4}\) The severity of illness of critical care patients and frequency of multiorgan failure explains this difference compared with general ward patient care. The percentages of prescriptions written owing to ‘incorrectly prescribed medications’ were comparable (5.2% and 7.5%, respectively), although the percentage on general wards was slightly higher, as already discussed.

The data presented in this evaluation are arguably an underestimate of pharmacist prescribing within the CCUs for several reasons. The utilisation of the e-prescribing system had some notable limitations inherent to the system used. First, prescribing is not searchable within the main database system. Discontinuation of medicines no longer indicated or that are inappropriate is an important prescribing activity that we are unable to report in the study. Second, medicines prescribed but not administered are similarly unrecordable (eg, ‘when required’ medications never administered do not register as having ever been prescribed).

In addition to the above, within this evaluation, no differentiation was made between transcribed medications (medications which had been started prior to critical care admission) and new prescriptions (medications initiated on critical care for an acute illness); the critical care units use e-prescribing, but the rest of the hospital use handwritten paper charts. All prescriptions on the e-prescribing system appear to be ‘new’ regardless of the actual start date, and it was not possible to retrospectively differentiate between transcribed and newly initiated medications. Pharmacists do not generally transcribe medications (transfer ward drug cards onto the electronic system) as this is considered the role of the junior doctors or advanced nurse practitioners; therefore, if transcribed medications were excluded from analysis, the proportion of prescriptions written by PIPs would likely increase. Overall, these limitations mean that the extent of critical care pharmacist prescribing as a percentage of all prescriptions is likely to be an underestimate.

CONCLUSION

Critical care pharmacists contributed a significant proportion of total prescriptions, with a wide scope of practice, prescribing mostly new medicines with a very low error rate.

Further multicentre studies are required to identify areas where critical care pharmacists should lead prescribing and medicines optimisation and how this impacts on patient outcomes.

Contributors All four authors (VC, JTP, M-CYLLM and RSB) contributed to the design of the work, data collection, analysis and interpretation; drafted the manuscript and revised it critically for important intellectual content; provided final approval of the version published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. There are no other contributors to be acknowledged in the publication of this manuscript.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES